|| Checking for direct PDF access through Ovid
To report our experience in complementing capecitabine with oxaliplatine in regard to tumour regression (efficacy), toxicity and surgical complications (safety) in thepreoperative treatment of locally advanced rectal cancer.Ninety patients were studied, capecitabin (Xeloda) was administered to 60 patients (66.7%), while 30 patients (33.3%) also received Oxaliplatin (Xelox). Radiotherapy to a dose of 50.4 Gy over 5 weeks was administered. Time interval between radiochemotherapy and surgery was 8 weeks.Gastrointestinal grade I-II toxicity was experienced by 23 patients (28.3% in Xeloda vs 20% Xelox). Grade III-IV toxicity was observed in further 18 patients (16.6% and 26.6% respectively). Skin and mucosa toxicity were experienced by 16 patients, 12 (20% in Xeloda and 13.3% in the Xelox arm). Good responders (Mandard Grades 1-2) were observed in 21 patients (35% Xeloda vs 50% Xelox). Major complications with necessary reoperation were seen in 11 patients (representing 10% in the Xeloda arm and 16.7% in the Xelox); minor complications were observed in 31 patients (35% and 33% respectively).Preoperative radiochemotherapy with capecitabin is safe and effective. Adding oxaliplatine to capecitabine shows an increase in good response rate to 50%, adding some more toxicity and surgical complications.